New pig-study·First-line animation and health care, new industry policies, new corporate trends, new veterinary drugs, new epidemic prevention technologies, private month update think tank, digital reading industry changes.
年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年Keqian Biological: annual inactivated vaccine 1.133 billion milliliters project reached production.
Recently, Keqian Biological stated on the investor interaction platform that the company's fundraising and investment project "animal biological products industrialization construction project" was completed and put into production at the end of March this year and passed the new version of GMP acceptance. As of now, the company has 15 intelligent production lines that have passed the GMP acceptance and obtained the "Veterinary Drug GMP Certificate" and "Veterinary Drug Production License".
After the project reaches full production, the annual production of inactivated vaccines is 1.133 billion milliliters, 390 million live vaccines for live animals, 3.3 billion live vaccines for poultry, and 30 million diagnostic reagents (feathers).
02 Jinhe Bio: invests 530 million in two years to build an upgraded animal vaccine production line. 530 million in two years to build an upgraded animal vaccine production line.
Jinhe Bio announced on September 22 that in 2020, Jinhe Bio approved by China Securities Regulatory Commission , and the actual net funds raised by the private placement of shares was approximately 802 million yuan. As of September 15, 2022, the company has used the private placement of funds raised a total of 530 million yuan, and the balance of unused funds raised is 268.8208 million yuan (including deposit interest income and handling fee expenditure).
From the use of the investment projects raised in the announcement, it can be seen that from 2020 to the present, Jinhe Biotech has invested at least 530 million yuan in the construction of animal vaccine production facilities and technological updates, and in the future, there will be about 270 million yuan in the balance of raised funds for the related production and operation of the main business of the animation insurance business.
03
Shenlian Bio: R&D investment in the first half of the year was 25.0687 million yuan, accounting for 18% of the total revenue
A few days ago, Shenlian Bio said at the semi-annual performance briefing that in the first half of the year, the company achieved a total operating income of 138 million yuan and R&D investment of 25.0687 million yuan, accounting for 18.13% of the operating income. In the past three years, the company's R&D investment accounted for more than 10% of its operating income, of which 19.14% of its R&D investment in 2021 were accounted for.
According to reports, Shenlian Bio's pig circular subunit vaccine is expected to obtain product approval documents this year and be launched for sale; swine fever genetic engineering subunit vaccine and cattle and sheep foot-and-mouth disease vaccine are expected to be launched for sale within the next two or three years.
Shenlian Bio has built and planned a number of production lines for veterinary biological products. Among them, production lines such as cell suspension culture foot-and-mouth disease inactivated vaccine, foot-and-mouth disease synthetic peptide vaccine, cell suspension culture virus subunit vaccine, immunology diagnostic products (Class A), molecular biology diagnostic products (Class B) have passed the GMP acceptance, and at the same time, the construction of live animal vaccines and inactivated animal vaccine production lines are accelerated. After all the above production lines are completed and put into production, they basically cover the production of all types of animal vaccine products and veterinary diagnostic products.
04
Ruipu Biology: and Hohhot City signed a framework agreement for the construction of biopharmaceutical industry cluster projects
Recently, Hohhot Municipal People's Government and Ruipu Biology signed a framework agreement for the construction of project construction of ruminant vaccines and drug preparation projects, pet vaccine production project construction, human vaccine research and development and production sharing platform, veterinary social services, industry-university-research cooperation, etc., and work together to build a first-class domestic biological vaccine development base, a demonstration base for biofermentation and pharmaceutical transformation and upgrading with a complete chain, and a distinctive China (Mongolia) pharmaceutical inheritance and development base, and build the biopharmaceutical industry cluster into an important growth pole for the high-quality economic development of the city.
In the first half of 2022, Rip Bio achieved operating income of 908 million yuan, a year-on-year decrease of 12.72%, and achieved net profit attributable to shareholders of listed companies of 139 million yuan, a year-on-year decrease of 31.32%. The company has 19 subsidiaries, 10 GMP production bases, 83 production lines, and more than 500 veterinary drug product approval numbers.
05
Qingdao Yibang: swine fever genetic engineering subunit vaccine (293T–E2) obtained a new veterinary drug certificate
Ministry of Agriculture and Rural Affairs Announcement No. 604 of September 28, approving the swine fever genetic engineering subunit vaccine (293T–E2) jointly applied by Qingdao Yibang Bioengineering Co., Ltd. and Guangzhou Bernitz Biotechnology Co., Ltd. as a new veterinary drug. The "New veterinary drug registration certificate" was issued, and the product process regulations, quality standards, instructions and labels were issued, which will be implemented from the date of publication.
06
Yongshun Bio: invested 12.1261 million in the first half of the year, and the overseas market continued to grow
On September 22, Yongshun Bio stated in the 2022 online collective reception day for investors of listed companies in Guangdong Province that the company invested 12.1261 million yuan in R&D expenses in the first half of the year, accounting for 7.80% of its operating income; it obtained 51 utility model patents and 2 approvals for clinical trials of veterinary biological products. As of June 30, 2022, the company has obtained a total of 22 authorized patents, including 13 invention patents and 59 utility model html; it has 18 new veterinary drug certificates and 31 production approval documents, participated in the research and development successfully and formulated 18 national veterinary biological products production procedures and quality standards.
In the first half of 2022, the company achieved operating income of 4.3821 million yuan abroad, and increased by 0.42% year-on-year. The company's overseas registered products have gradually been recognized by customers after preliminary market cultivation and promotion. At present, 7 products have completed export registration. With the stability of the new crown pneumonia epidemic in the future, the export business will be more smooth.
07
Shihuanowbevi: revise the inactivated vaccine of pig cyclovirus type 2 (1010 strains) registration
Ministry of Agriculture and Rural Affairs Announcement No. 598 on September 5, according to the provisions of the " Veterinary Drug Management Regulations " and the "Veterinary Drug Registration Measures", after review, Nanchang Boehringer Ingelheim Animal Health Co., Ltd. was approved to revise the live vaccine of chicken viral arthritis (S1133 strain) and Zhejiang Shihuanowbevi Biotechnology Co., Ltd. revise the process regulations, quality standards, instructions and labels of two veterinary drug products of pig cyclovirus type 2 (1010 strains). Implemented from the date of publication.
08 Haizheng Animal Protection: Approve the registration of Terramycin raw materials and injection products for pigs. Approve the registration of Terramycin raw materials and injection products for pigs.
Ministry of Agriculture and Rural Affairs on September 13: According to the provisions of the "Veterinary Drug Administration Regulations" and the "Veterinary Drug Registration Measures", after review, the registration of Terramycin , including three units, including Haizheng Pharmaceutical Nantong Co., Ltd., Zhejiang Haizheng Animal Health Products Co., Ltd., and Zhejiang Haizheng Pharmaceutical Co., Ltd. and Terramycin injection product registration applied by Zhejiang Haizheng Animal Health Products Co., Ltd., and the product process regulations, quality standards, instructions and labels were issued. Implemented from the date of publication.
This article is from New Pigpai
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-